Evidence map›Paper›PMID 34646906›Full record

ArticleOpen forum infectious diseases2021

Corticosteroids Do Not Increase the Likelihood of Primary

Travis J Carlson, Anne J Gonzales-Luna, Melissa F Wilcox, Sarah G Theriault, Faris S Alnezary, Pankaj Patel, Bumhee K Ahn, Evan J Zasowski, Kevin W Garey

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Incidence and Risk Factors forMicroorganisms · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Travis J CarlsonDepartment of Clinical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, North Carolina, USA.ORCID https://orcid.org/0000-0001-9564-3030
Anne J Gonzales-LunaDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.ORCID https://orcid.org/0000-0003-1906-359X
Melissa F WilcoxDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.
Sarah G TheriaultDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.
Faris S AlnezaryDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.
Pankaj PatelDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.
Bumhee K AhnDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.
Evan J ZasowskiDepartment of Clinical Sciences, Touro University College of Pharmacy, Vallejo, California, USA.
Kevin W GareyDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas,USA.ORCID https://orcid.org/0000-0003-2063-7503
University of Houston · USHigh Point University · USTaibah University · SATouro University California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pathogenesis of

methodsThis was a case-control study of hospitalized adults. The case population included patients diagnosed with primary CDI who received at least 1 dose of a high-risk antibiotic (cefepime, meropenem, or piperacillin-tazobactam) in the 90 days before CDI diagnosis. The control population included patients who received at least 1 dose of the same high-risk antibiotic but did not develop CDI in the 90 days following their first dose of antibiotic. The primary study outcome was the development of CDI based on receipt of corticosteroids.

resultsThe final study cohort consisted of 104 cases and 153 controls. Those who received corticosteroids had a lower odds of CDI after adjusting for age, proton pump inhibitor use, and antibiotic days of therapy (odds ratio, 0.54; 95% CI, 0.30-0.97;

conclusionsWe demonstrated a 46% relative reduction in the odds of developing CDI in patients who received corticosteroids in the past 90 days. We believe that our results provide the best clinical evidence to further support mechanistic studies underlying this phenomenon.

Indexed as

antibioticClostridium difficilecorticosteroiddiarrheasteroid

Identifiers

PMID34646906
PMCPMC8501294
OpenAlexW3190161358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.